Diagnostic and therapeutic applications of recombinant antibodies: Targeting the extra-domain B of fibronectin, a marker of tumor angiogenesis

Current Pharmaceutical Design

Volumn 10, Issue 13, 2004, Pages 1537-1549

  Ebbinghaus, Christina ^a   Scheuermann, Jörg ^a   Neri, Dario ^a   Elia, Giuliano ^a  

^a ETH ZURICH   (Switzerland)

Author keywords

Angiogenesis; Antibody; ED B; Fibronectin; Phage display; ScFv; Tumor targeting

Indexed keywords

ALPHA2 INTEGRIN; ALPHA5 INTEGRIN; BETA3 INTEGRIN; BISMUTH 213; CYTOKINE; ENDOGLIN; FIBRONECTIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HERMES ANTIGEN; IMMUNOGLOBULIN E; INTERLEUKIN 2; ISOPROTEIN; LIGAND; LIPOSOME; MELPHALAN; MESSENGER RNA PRECURSOR; MONOCLONAL ANTIBODY; ONCOFETAL ANTIGEN; PHOTOSENSITIZING AGENT; POLYCLONAL ANTIBODY; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RADIOISOTOPE; RECOMBINANT ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TUMOR MARKER; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ALTERNATIVE RNA SPLICING; CARCINOGENESIS; DIAGNOSTIC TEST; DRUG DELIVERY SYSTEM; DRUG TARGETING; EXTRACELLULAR MATRIX; HUMAN; METASTASIS; METHODOLOGY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN STRUCTURE; REVIEW; SIDE EFFECT; SOLID TUMOR;

ANIMALS; ANTIBODIES; DRUG DELIVERY SYSTEMS; FIBRONECTINS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 2342427004     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043384808     Document Type: Review

References (114)

1. Bischoff J. Approaches to studying cell adhesion molecules in angiogenesis. Trends in cell biology 1995; 5: 69-73.
2. Folkman J. Clinical applications of research on angiogenesis. Seminars in medicine of the Beth Israel Hospital Boston 1995; 333: 1757-1763.
3. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1(1): 27-31.
4. Bosslet K, Straub R, Blumrich M, Czech J, Gerken M, Sperker B, et al. Elucidation of the mechanism enabling tumor selective prodrug monotherapy. Cancer Res 1998; 58(6): 1195-201.
5. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285(21): 1182-6.
6. Folkman J. Angiogenesis in psoriasis: therapeutic implications. J Invest Dermatol 1972; 59(1): 40-3.
7. Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 1972; 175(3): 409-16.
8. Hanahan D. A flanking attack on cancer. Nat Med 1998; 4(1): 13-4.
9. Blood CH, Zetter BR. Tumor interactions with the vasculature: angiogenesis and tumor metastasis. Biochim Biophys Acta 1990; 1032(1): 89-118.
10. Zetter BR. On target with tumor blood vessel markers. Nat Biotechnol 1997; 15(12): 1243-4.
11. Gougos A, Letarte M. Primary structure of endoglin, an RGD-containing glycoprotein of human endothelial cells. J Biol Chem 1990; 265(15): 8361-4.
12. Brekken RA, Huang X, King SW, Thorpe PE. Vascular endothelial growth factor as a marker of tumor endothelium. Cancer Res 1998; 58(9): 1952-9.
13. Ran S, Gao B, Duffy S, Watkins L, Rote N, Thorpe PE. Infarction of solid Hodgkin's tumors in mice by antibody-directed targeting of tissue factor to tumor vasculature. Cancer Res 1998; 58(20): 4646-53.
14. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA. Definition of two angiogenic pathways by distinct alpha v integrins. Science 1995; 270(5241): 1500-2.
15. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994; 79(7): 1157-64.
16. Chang SS, O'Keefe DS, Bacich DJ, Reuter VE, Heston WD, Gaudin PB. Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res 1999; 5(10): 2674-81.
17. Griffioen AW, Coenen MJ, Damen CA, Hellwig SM, van Weering DH, Vooys W, et al. CD44 is involved in tumor angiogenesis; an activation antigen on human endothelial cells. Blood 1997; 90(3): 1150-9.
18. Zardi L, Carnemolla B, Siri A, Petersen TE, Paolella G, Sebastio G, et al. Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon. EMBO J 1987; 6(8): 2337-42.
19. St Croix B, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E, et al. Genes expressed in human tumor endothelium. Science 2000; 289(5482): 1197-202.
20. Hynes RO. Fibronectins. New York, NY: Springer Verlag Inc; 1990.
21. Magnusson MK, Zhank Q, Mosher DF. In: Cell adhesion molecules and matrix proteins: Role in health and diseases (S.A. Mousa, ed.). Springer Verlag, Berlin and Heidelberg, 1998; pp. 219-40.
22. Hynes R. Molecular biology of fibronectin. Annu Rev Cell Biol 1985; 1: 67-90.
23. Yamada KM. Cell surface interactions with extracellular materials. Annu Rev Biochem 1983; 52: 761-99.
24. Ruoslahti E. Fibronectin and its receptors. Annu Rev Biochem 1988; 57: 375-413.
25. Alitalo K, Vaheri A. Pericellular matrix in malignant transformation. Adv Cancer Res 1982; 37: 111-58.
26. Leahy DJ, Aukhil I, Erickson HP. 2.0 A crystal structure of a four-domain segment of human fibronectin encompassing the RGD loop and synergy region. Cell 1996; 84(1): 155-64.
27. George EL, Georges-Labouesse EN, Patel-King RS, Rayburn H, Hynes RO. Defects in mesoderm, neural tube and vascular development in mouse embryos lacking fibronectin. Development 1993; 119(4): 1079-91.
28. Castellani P, Siri A, Rosellini C, Infusini E, Borsi L, Zardi L. Transformed human cells release different fibronectin variants than do normal cells. J Cell Biol 1986; 103(5): 1671-7.
29. Borsi L, Carnemolla B, Castellani P, Rosellini C, Vecchio D, Allemanni G, et al. Monoclonal antibodies in the analysis of fibronectin isoforms generated by alternative splicing of mRNA precursors in normal and transformed human cells. J Cell Biol 1987; 104(3): 595-600.
30. Vartio T, Laitinen L, Narvanen O, Cutolo M, Thornell LE, Zardi L, et al. Differential expression of the ED sequence-containing form of cellular fibronectin in embryonic and adult human tissues. J Cell Sci 1987; 88(Pt 4): 419-30.
31. Carnemolla B, Balza E, Siri A, Zardi L, Nicotra MR, Bigotti A, et al. A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors. J Cell Biol 1989; 108(3): 1139-48.
32. Oyama F, Hirohashi S, Shimosato Y, Titani K, Sekiguchi K. Deregulation of alternative splicing of fibronectin pre-mRNA in malignant human liver tumors. J Biol Chem 1989; 264(18): 10331-4.
33. Oyama F, Hirohashi S, Shimosato Y, Titani K, Sekiguchi K. Oncodevelopmental regulation of the alternative splicing of fibronectin pre-messenger RNA in human lung tissues. Cancer Res 1990; 50(4): 1075-8.
34. Borsi L, Balza E, Allemanni G, Zardi L. Differential expression of the fibronectin isoform containing the ED-B oncofetal domain in normal human fibroblast cell lines originating from different tissues. Exp Cell Res 1992; 199(1): 98-105.
35. Castellani P, Viale G, Dorcaratto A, Nicolo G, Kaczmarek J, Querze G, et al. The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis. Int J Cancer 1994; 59(5): 612-8.
36. Kaczmarek J, Castellani P, Nicolo G, Spina B, Allemanni G, Zardi L. Distribution of oncofetal fibronectin isoforms in normal, hyperplastic and neoplastic human breast tissues. Int J Cancer 1994; 59(1): 11-6.
37. Borsi L, Allemanni G, Castellani P, Rosellini C, Di Vinci A, Zardi L. Structural differences in the cell binding region of human fibronectin molecules isolated from cultured normal and tumor-derived human cells. FEBS Lett 1985; 192(1): 71-4.
38. Carnemolla B, Neri D, Castellani P, Leprini A, Neri G, Pini A, et al. Phage antibodies with pan-species recognition of the oncofoetal angiogenesis marker fibronectin ED-B domain. Int J Cancer 1996; 68(3): 397-405.
39. Fattorusso R, Pellecchia M, Viti F, Neri P, Neri D, Wuthrich K. NMR structure of the human oncofoetal fibronectin ED-B domain, a specific marker for angiogenesis. Structure Fold Des 1999; 7(4): 381-90.
40. Ffrench-Constant C, Hynes RO. Alternative splicing of fibronectin is temporally and spatially regulated in the chicken embryo. Development 1989; 106(2): 375-88.
41. Ffrench-Constant C, Van de Water L, Dvorak HF, Hynes RO. Reappearance of an embryonic pattern of fibronectin splicing during wound healing in the adult rat. J Cell Biol 1989; 109(2): 903-14.
42. Laitinen L, Vartio T, Virtanen I. Cellular fibronectins are differentially expressed in human fetal and adult kidney. Lab Invest 1991; 64(4): 492-8.
43. Birchler M, Viti F, Zardi L, Spiess B, Neri D. Selective targeting and photocoagulation of ocular angiogenesis mediated by a phage-derived human antibody fragment. Nat Biotechnol 1999; 17(10): 984-8.
44. Birchler MT, Milisavlijevic D, Pfaltz M, Neri D, Odermatt B, Schmid S, et al. Expression of the extra domain B of fibronectin, a marker of angiogenesis, in head and neck tumors. Laryngoscope 2003; 113(7): 1231-7.
45. Pujuguet P, Hammann A, Moutet M, Samuel JL, Martin F, Martin M. Expression of fibronectin ED-A+ and ED-B+ isoforms by human and experimental colorectal cancer. Contribution of cancer cells and tumor- associated myofibroblasts. Am J Pathol 1996; 148(2): 579-92.
46. D'Ovidio MC, Mastracchio A, Marzullo A, Ciabatta M, Pini B, Uccini S, et al. Intratumoral microvessel density and expression of ED-A/ED-B sequences of fibronectin in breast carcinoma. Eur J Cancer 1998; 34(7): 1081-5.
47. Karelina TV, Eisen AZ. Interstitial collagenase and the ED-B oncofetal domain of fibronectin are markers of angiogenesis in human skin tumors. Cancer Detect Prev 1998; 22(5): 438-44.
48. Midulla M, Verma R, Pignatelli M, Ritter MA, Courtenay-Luck NS, George AJ. Source of oncofetal ED-B-containing fibronectin: implications of production by both tumor and endothelial cells. Cancer Res 2000; 60(1): 164-9.
49. Viti F, Tarli L, Giovannoni L, Zardi L, Neri D. Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis. Cancer Res 1999; 59(2): 347-52.
50. Fukuda T, Yoshida N, Kataoka Y, Manabe R, Mizuno-Horikawa Y, Sato M, et al. Mice lacking the EDB segment of fibronectin develop normally but exhibit reduced cell growth and fibronectin matrix assembly in vitro. Cancer Res 2002; 62(19): 5603-10.
51. Peters JH, Trevithick JE, Johnson P, Hynes RO. Expression of the alternatively spliced EIIIB segment of fibronectin. Cell Adhes Commun 1995; 3(1): 67-89.
52. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256(5517): 495-7.
53. Carnemolla B, Leprini A, Allemanni G, Saginati M, Zardi L. The inclusion of the type III repeat ED-B in the fibronectin molecule generates conformational modifications that unmask a cryptic sequence. J Biol Chem 1992; 267(34): 24689-92.
54. Mariani G, Lasku A, Balza E, Gaggero B, Motta C, Di Luca L, et al. Tumor targeting potential of the monoclonal antibody BC-1 against oncofetal fibronectin in nude mice bearing human tumor implants. Cancer 1997; 80(12 Suppl): 2378-84.
55. Smith GP. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 1985; 228(4705): 1315-7.
56. McCafferty J, Griffiths AD, Winter G, Chiswell DJ. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 1990; 348(6301): 552-4.
57. Winter G, Griffiths AD, Hawkins RE, Hoogenboom HR. Making antibodies by phage display technology. Annu Rev Immunol 1994; 12: 433-55.
58. Bird RE, Hardman KD, Jacobson JW, Johnson S, Kaufman BM, Lee SM, et al. Single-chain antigen-binding proteins. Science 1988; 242(4877): 423-6.
59. Huston JS, Levinson D, Mudgett-Hunter M, Tai MS, Novotny J, Margolies MN, et al. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci USA 1988; 85(16): 5879-83.
60. Nissim A, Hoogenboom HR, Tomlinson IM, Flynn G, Midgley C, Lane D, et al. Antibody fragments from a 'single pot' phage display library as immunochemical reagents. EMBO J 1994; 13(3): 692-8.
61. Neri D, Carnemolla B, Nissim A, Leprini A, Querze G, Balza E, et al. Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform. Nat Biotechnol 1997; 15(12): 1271-5.
62. Pini A, Viti F, Santucci A, Carnemolla B, Zardi L, Neri P, et al. Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J Biol Chem 1998; 273(34): 21769-76.
63. Viti F, Nilsson F, Demartis S, Huber A, Neri D. Design and use of phage display libraries for the selection of antibodies and enzymes. Methods Enzymol 2000; 326: 480-505.
64. Dreher ML, Gherardi E, Skerra A, Milstein C. Colony assays for antibody fragments expressed in bacteria. J Immunol Methods 1991; 139(2): 197-205.
65. Skerra A, Dreher ML, Winter G. Filter screening of antibody Fab fragments secreted from individual bacterial colonies: specific detection of antigen binding with a two- membrane system. Anal Biochem 1991; 196(1): 151-5.
66. Giovannoni L, Viti F, Zardi L, Neri D. Isolation of anti-angiogenesis antibodies from a large combinatorial repertoire by colony filter screening. Nucleic Acids Res 2001; 29(5): E27.
67. Frank R, Overwin H. SPOT synthesis. Epitope analysis with arrays of synthetic peptides prepared on cellulose membranes. Methods Mol Biol 1996; 66: 149-69.
68. Scheuermann J, Volonterio A, Zerbe O, Zanda M, Neri D. Discovery and investigation of lead-compounds as binders to the extra-domain B of the angiogenesis marker, fibronectin. Drug development research 2003; 58: 268-282.
69. Fraker PJ, Speck JC, Jr. Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. Biochem Biophys Res Commun 1978; 80(4): 849-57.
70. Garg PK, Archer GE Jr, Bigner DD, Zalutsky MR. Synthesis of radioiodinated N-succinimidyl iodobenzoate: optimization for use in antibody labelling. Int J Rad Appi Instrum [A] 1989; 40(6): 485-90.
71. Demartis S, Tarli L, Borsi L, Zardi L, Neri D. Selective targeting of tumour neovasculature by a radiohalogenated human antibody fragment specific for the ED-B domain of fibronectin. Eur J Nucl Med 2001; 28(4): 534-9.
72. McDevitt MR, Barendswaard E, Ma D, Lai L, Curcio MJ, Sgouros G, et al. An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer. Cancer Res 2000; 60(21): 6095-100.
73. Folli S, Westermann P, Braichotte D, Pelegrin A, Wagnieres G, van den Bergh H, et al. Antibody-indocyanin conjugates for immunophotodetection of human squamous cell carcinoma in nude mice. Cancer Res 1994; 54(10): 2643-9.
74. Birchler M, Neri G, Tarli L, Halin C, Viti F, Neri D. Infrared photodetection for the in vivo localisation of phage-derived antibodies directed against angiogenic markers. J Immunol Methods 1999; 231(1-2): 239-48.
75. Mariani G, Lasku A, Pau A, Villa G, Motta C, Calcagno G, et al. A pilot pharmacokinetic and immunoscintigraphic study with the technetium-99m-labeled monoclonal antibody BC-1 directed against oncofetal fibronectin in patients with brain tumors. Cancer 1997; 80(12 Suppl): 2484-9.
76. Santimaria M, Moscatelli G, Viale GL, Giovannoni L, Neri G, Viti F, et al. Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin Cancer Res 2003; 9(2): 571-9.
77. Mann DA, Frankel AD. Endocytosis and targeting of exogenous HIV-1 Tat protein. EMBO J 1991; 10(7): 1733-9.
78. Green M, Loewenstein PM. Autonomous functional domains of chemically synthesized human immunodeficiency virus tat transactivator protein. Cell 1988; 55(6): 1179-88.
79. Frankel AD, Pabo CO. Cellular uptake of the tat protein from human immunodeficiency virus. Cell 1988; 55(6): 1189-93.
80. Niesner U, Halin C, Lozzi L, Gunthert M, Neri P, Wunderli-Allenspach H, et al. Quantitation of the tumor-targeting properties of antibody fragments conjugated to cell-permeating HIV-1 TAT peptides. Bioconjug Chem 2002; 13(4): 729-36.
81. Halin C, Niesner U, Villani ME, Zardi L, Neri D. Tumor-targeting properties of antibody-vascular endothelial growth factor fusion proteins. Int J Cancer 2002; 102(2): 109-16.
82. Grana C, Chinol M, Robertson C, Mazzetta C, Bartolomei M, De Cicco C, et al. Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: a pilot study. Br J Cancer 2002; 86(2): 207-12.
83. Neri D, de Lalla C, Petrul H, Neri P, Winter G. Calmodulin as a versatile tag for antibody fragments. Biotechnology (N Y) 1995; 13(4): 373-7.
84. Melkko S, Halin C, Borsi L, Zardi L, Neri D. An antibody-calmodulin fusion protein reveals a functional dependence between macromolecular isoelectric point and tumor targeting performance. Int J Radiation Oncology Biol Phys 2002; 54(5).
85. Halin C, Rondini S, Nilsson F, Berndt A, Kosmehl H, Zardi L, et al. Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature. Nat Biotechnol 2002; 20(3): 264-9.
86. Halin C, Gafner V, Villani ME, Borsi L, Berndt A, Kosmehl H, et al. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha. Cancer Res 2003; 63(12): 3202-10.
87. Borsi L, Balza E, Bestagno M, Castellani P, Carnemolla B, Biro A, et al. Selective targeting of tumoral vasculature: Comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int J Cancer 2002; 102(1): 75-85.
88. Nicolo M, Biro A, Cardillo-Piccolino F, Castellani P, Giovannini A, Mariotti C, et al. Expression of extradomain-B-containing fibronectin in subretinal choroidal neovascular membranes. Am J Ophthalmol 2003; 135(1): 7-13.
89. Huang X, Molema G, King S, Watkins L, Edgington TS, Thorpe PE. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 1997; 275(5299): 547-50.
90. Nilsson F, Kosmehl H, Zardi L, Neri D. Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res 2001; 61(2): 711-6.
91. Rosenberg SA, Yang JC, White DE, Steinberg SM. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg 1998; 228(3): 307-19.
92. Ruef C, Coleman DL. Granulocyte-macrophage colony-stimulating factor: pleiotropic cytokine with potential clinical usefulness. Rev Infect Dis 1990; 12(1): 41-62.
93. Tsung K, Meko JB, Peplinski GR, Tsung YL, Norton JA. IL-12 induces T helper 1-directed antitumor response. J Immunol 1997; 158(7): 3359-65.
94. Carnemolla B, Borsi L, Balza E, Castellani P, Meazza R, Berndt A, et al. Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood 2002; 99(5): 1659-65.
95. Lienard D, Ewalenko P, Delmotte JJ, Renard N, Lejeune FJ. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992; 10(1): 52-60.
96. Eggermont AM, Schraffordt Koops H, Lienard D, Kroon BB, van Geel AN, Hoekstra HJ, et al. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol 1996; 14(10): 2653-65.
97. Eggermont AM. TNF registered in Europe: does TNF get a second chance? J Immunother 2000; 23(4): 505-6.
98. Barbara JA, Smith WB, Gamble JR, Van Ostade X, Vandenabeele P, Tavernier J, et al. Dissociation of TNF-alpha cytotoxic and proinflammatory activities by p55 receptor- and p75 receptor-selective TNF-alpha mutants. EMBO J 1994; 13(4): 843-50.
99. van der Veen AH, Eggermont AM, Seynhaeve AL, van T, ten Hagen TL. Biodistribution and tumor localization of stealth liposomal tumor necrosis factor-alpha in soft tissue sarcoma bearing rats. Int J Cancer 1998; 77(6): 901-6.
100. Moro M, Pelagi M, Fulci G, Paganelli G, Dellabona P, Casorati G, et al. Tumor cell targeting with antibody-avidin complexes and biotinylated tumor necrosis factor alpha. Cancer Res 1997; 57(10): 1922-8.
101. Curnis F, Sacchi A, Borgna L, Magni F, Gasparri A, Corti A. Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol 2000; 18(11): 1185-90.
102. Pietersz GA, Wenjun L, Krauer K, Baker T, Wreschner D, McKenzie IF. Comparison of the biological properties of two antimucin-1 antibodies prepared for imaging and therapy. Cancer Immunol Immunother 1997; 44(6): 323-8.
103. Gillies SD, Young D, Lo KM, Roberts S. Biological activity and in vivo clearance of antitumor antibody/cytokine fusion proteins. Bioconjug Chem 1993; 4(3): 230-5.
104. Cooke SP, Pedley RB, Boden R, Begent RH, Chester KA. In vivo tumor delivery of a recombinant single chain Fv: tumor necrosis factor-alpha fusion [correction of factor: a fusion] protein. Bioconjug Chem 2002; 13(1): 7-15.
105. Curnis F, Sacchi A, Corti A. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J Clin Invest 2002; 110(4): 475-82.
106. Borsi L, Balza E, Carnemolla B, Sassi F, Castellani P, Berndt A, et al. Selective targeted delivery of TNF{alpha} to tumor blood vessels. Blood 2003; 102: 4384-92.
107. Mastrobattista E, Koning GA, Storm G. Immunoliposomes for the targeted delivery of antitumor drugs. Adv Drug Deliv Rev 1999; 40(1-2): 103-127.
108. de Kruif J, Storm G, van Bloois L, Logtenberg T. Biosynthetically lipid-modified human scFv fragments from phage display libraries as targeting molecules for immunoliposomes. FEBS Lett 1996; 399(3): 232-6.
109. Hansen CB, Kao GY, Moase EH, Zalipsky S, Allen TM. Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures. Biochim Biophys Acta 1995; 1239(2): 133-44.
110. Schwendener RA, Trub T, Schott H, Langhals H, Barth RF, Groscurth P, et al. Comparative studies of the preparation of immunoliposomes with the use of two bifunctional coupling agents and investigation of in vitro immunoliposome-target cell binding by cytofluorometry and electron microscopy. Biochim Biophys Acta 1990; 1026(1): 69-79.
111. Marty C, Odermatt B, Schott H, Neri D, Ballmer-Hofer K, Klemenz R, et al. Cytotoxic targeting of F9 teratocarcinoma tumours with anti-ED-B fibronectin scFv antibody modified liposomes. Br J Cancer 2002; 87(1): 106-12.
112. Milenic DE. Monoclonal antibody-based therapy strategies: providing options for the cancer patient. Curr Pharm Design 2002; 8(19): 1749-64.
113. Pearlman JD, Laham RJ, Post M, Leiner T, Simons M. Medical imaging techniques in the evaluation of strategies for therapeutic angiogenesis. Curr Pharm Design 2002; 8(16): 1467-96.
114. Richardson PL. The determination and use of optimized protease substrates in drug discovery and development. Curr Pharm Design 2002; 8(28): 2559-81.